Search the Newsreel

DGX|Quest Diagnostics Inc|Price:233.010|Chg%:-1.190

This article provides an overview of Quest Diagnostics Inc. (DGX), detailing its current stock performance, key financial figures, and analyst ratings. The company is highlighted for its healthy fundamentals, high growth potential, and strong institutional ownership, with analysts generally rating it as a "Buy" …

Quest Diagnostics Incorporated (DGX) jumps 8.2% as volume nearly doubles

The diagnostics stock’s weekly advance gained confirmation from heavier turnover and positive momentum readings.

Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?

Quest Diagnostics Incorporated DGX has rallied as earnings momentum improved, estimates moved higher and demand broadened across its testing platform. The buy case is not one-sided. The stock's advance has lifted valuation closer to its five-year high, while leverage, cost pressure and reimbursement uncertainty …

AQST|Aquestive Therapeutics Inc|Price:3.725|Chg%:+0.125

This article provides a comprehensive stock analysis of Aquestive Therapeutics Inc (AQST) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company has healthy fundamentals, high growth potential, and its valuation is considered fairly …

Quest Diagnostics’ 8.6M-share advance tightens the chase toward its 52-week high

DGX gained 8.2% in the latest week on twice its 13-week volume average, leaving the clinical-lab stock 4.2% below its 52-week high while valuation and reversal risk argue for confirmation.

Discipline and Rules-Based Execution in HQI Response

This article provides an AI-driven analysis for Hirequest, Inc. (NYSE: HQI), highlighting a strong "Overweight Bias" based on sentiment across all horizons. It identifies a mid-channel oscillation pattern and an exceptional 40.5:1 risk-reward setup targeting a 12.7% gain. The report includes three distinct trading …

Argus Research Adjusts Quest Diagnostics Price Target to $260 From $225, Maintains Buy Rating

Argus Research has increased its price target for Quest Diagnostics (DGX) to $260 from $225, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the company's future performance. The article also notes other recent analyst adjustments for Quest …

Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026

Quest Diagnostics (DGX) is propelled by broad testing demand, expanded payer access, advanced diagnostics, and strategic partnerships, supporting revenue growth in 2026. The company's base business benefits from physician, hospital, and consumer channels, while advanced diagnostics in multiple health areas and acquisitions contribute significantly. …

Labcorp raises annual profit forecast on strong testing demand

By Sahil Pandey July 30 (Reuters) - Laboratory operator Labcorp raised its annual profit forecast and posted better-than-expected second-quarter results on Thursday, ‌as steady demand for diagnostic testing and growth in ‌its drug-development services business boosted performance. Shares of the company fell about 6% …

Bacterial vaginosis patients were over 3x more likely to have an STI

A national study by Quest Diagnostics and Hologic, analyzing data from over 1.5 million U.S. women, found that 12% of women positive for bacterial vaginosis (BV) also had at least one non-viral sexually transmitted infection (STI), compared to 3.8% of BV-negative women. BV positivity …

QUEST DIAGNOSTICS INC : JP MORGAN RAISES TARGET PRICE TO $250 FROM $220

JP Morgan has increased its target price for Quest Diagnostics Inc. from $220 to $250. This change in target price suggests an updated positive outlook for the company's stock by the financial institution. The specific reasons for this revised target are not detailed in …

HQI|Hirequest Inc|Price:13.680|Chg%:-0.135

This article provides a comprehensive stock analysis of Hirequest Inc (HQI) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Professional & Commercial Services industry. Key insights include high institutional ownership, a Strong Buy rating from analysts with an …

AusQuest expands copper-gold footprint with strong Cangallo drilling and funded Australian programs

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $248.86, Implies 6% Upside

The average 12-month price target for Quest Diagnostics Incorporated (DGX) stock has been raised by analysts from $246.6 to $248.86, indicating an approximate 6% potential upside from its July 29th closing price. The consensus rating from 20 analysts remains a "Buy," with 9 Buys, …

Quest Diagnostics SVP Mark Delaney sells $376k in shares

Mark E. Delaney, SVP and CCO at Quest Diagnostics Inc. (NASDAQ: DGX), sold 1,600 shares for $376,288 on July 28, 2026, conducted under a Rule 10b5-1 sales plan. This transaction occurred as the stock neared its 52-week high, after a significant 12% gain. The …

Quest Diagnostics Incorporated (DGX) draws heavier weekly trading as trend stays active

The healthcare diagnostics stock extended its weekly advance, with volume and momentum readings adding confirmation rather than contradiction.

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics (NASDAQ: AQST) will release its second quarter 2026 financial results and provide business updates after market close on August 11, 2026. The company will then host a conference call for investors on August 12, 2026, at 8:00 a.m. ET to discuss these …

Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aquestive Therapeutics Inc (AQST), highlighting its current price momentum score, support and resistance levels, and indicator readings. It details various technical indicators like MACD, RSI, and moving averages, offering "Sell", "Neutral", and "Buy" signals. The analysis suggests …

QRHC|Quest Resource Holding Corp|Price:1.320|Chg%:+0.070

TradingKey provides a comprehensive analysis of Quest Resource Holding Corp (QRHC), highlighting its stable fundamentals, significant growth potential, and fair valuation within the Professional & Commercial Services industry. Analysts have rated QRHC as a Buy, with a target price indicating substantial upside. Despite strong …

Quest Resource Holding Corp (QRHC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Quest Resource Holding Corp (QRHC), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 31, 2026, QRHC has a price momentum score of 4.25 and is trading …

Hirequest Inc (HQI) Institutional Confidence

This article analyzes the institutional confidence in Hirequest Inc (HQI), reporting a current institutional shareholding score of 3.00, ranking it 115 out of 160 in its industry. The institutional shareholding proportion has increased by 13.98% quarter-over-quarter, with James Simons identified as the largest institutional …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to join the investigation. …

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Quest Diagnostics Inc. (DGX) stock saw gains on Tuesday, rising 1.77% to $235.94, marking its second consecutive day of increases. Despite this daily advance and a positive overall market trend with the S&P 500 and Dow Jones also rising, Quest Diagnostics Inc. underperformed compared …

Quest Diagnostics Incorporated (DGX) volume expands in 52-week weekly setup

The diagnostics stock combined recent price strength with active trend confirmation as weekly turnover ran well above normal.

Form 4 Quest Diagnostics orporated For: 28 July By Investing.com

This article from Investing.com is a standard Form 4 filing for Quest Diagnostics (DGX) on July 28. It provides a brief mention of the filing and some stock market data. The article appears to be a stub for regulatory filings, providing minimal content beyond …

EnQuest PLC Revenue Breakdown – LSE:ENQ

Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis

Quest Diagnostics Inc (DGX) currently holds a valuation score of 9.04, placing it 24th out of 75 in the Healthcare Providers & Services industry. Its P/E ratio stands at 25.17, which is at its recent high and significantly above its recent low. However, relevant …

Hirequest Inc (HQI) Cash Flow

This article provides a detailed historical overview of Hirequest Inc's (HQI) cash flow statements, including operating, investing, and financing activities, presented quarterly and annually. It features specific financial figures for various fiscal quarters and years, along with year-over-year percentage changes. The article also includes …

Quest Diagnostics (NYSE: DGX) SVP acquires 34.0000 shares via dividend reinvestment

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc. (NYSE: DGX), acquired 34.0000 shares of common stock at $206.807 per share through a dividend reinvestment plan. This transaction, reported early on Form 4, increased his direct holdings to 11,935.0000 shares, though …

Aquestive Therapeutics Inc (AQST) Institutional Confidence

Aquestive Therapeutics Inc (AQST) has an institutional shareholding score of 5.00, placing it 72nd within the Pharmaceuticals industry. Institutional investors collectively hold 60.30% of the shares, marking a 16.75% increase quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 912.50K shares.

Quest Resource Holding Corp (QRHC) Cash Flow

This article provides a detailed cash flow statement for Quest Resource Holding Corp (QRHC), including operating, investing, and financing cash flows presented quarterly and annually. It highlights key financial figures such as a 9.56M operating cash flow in FY2025, a 257.06% year-over-year increase, and …

Quest Resource Holding Corp (QRHC) Balance Sheet

This article provides detailed quarterly and annual balance sheet data for Quest Resource Holding Corp (QRHC), allowing users to analyze its financial health. It includes key metrics such as cash and short-term investments, receivables, total assets, various liabilities, and shareholders' equity over multiple fiscal …

Rothschild & Co Redburn Adjusts Quest Diagnostics Price Target to $251 From $233, Maintains Buy Rating

Rothschild & Co Redburn has increased its price target for Quest Diagnostics (NYSE: DGX) to $251, up from $233, while maintaining a Buy rating on the stock. This adjustment suggests a positive outlook from the firm regarding Quest Diagnostics' future performance.

Hirequest Inc (HQI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Hirequest Inc (HQI), detailing its current price momentum score of 3.62 within the Professional & Commercial Services industry. It highlights the stock's trading range between resistance at 14.46 and support at 12.61, suitable for swing trading. The …

HireQuest Sets Q2 2026 Results Call for Aug. 10

HireQuest (Nasdaq: HQI) announced it will host a conference call on Monday, August 10, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter ended June 30, 2026. Investors can access the call via toll-free and international dial-in numbers …

HireQuest to Hold Second Quarter 2026 Financial Results Conference Call on Monday, August 10, 2026

HireQuest (Nasdaq: HQI) announced it will host a conference call on Monday, August 10, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter ended June 30, 2026. Interested parties can access the call via toll-free or international dial-in …